Skip to main content

Table 1 Overview of the intended chemotherapy protocol (* patients treated 2009–2013, ** patients treated 2005–2008, i.v. = intravenous, MTX = methotrexate, AraC = cytarabine, i.th. = intrathecal)

From: HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis

  Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
Cycle 1–3 (1 cycle = 2 weeks)
- Rituximab 500 mg/m2 i.v.* x       
- MTX 3000–5000 mg/m2 i.v.   x      
- Ifosfamide 800 mg/m2 i.v.    x x x   
- Liposomal AraC 50 mg i.th.**    x     
Cycle 4 + 6 (1 cycle = 3 weeks)
- Cytarabine 3000 mg/m2 i.v   x x     
- Liposomal AraC 50 mg i.th.**     x    
- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)*     x x x  
- AraC 10 mg intraventricular (patients < 65 ys)*        x
Cycle 5 (1 cycle = 2 weeks)
- MTX 3000–5000 mg/m2 i.v.   x      
- Ifosfamide i.v. 800 mg/m2 i.v.    x x x  
- Liposomal AraC 50 mg i.th.**    x    
- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)*    x x x  
- AraC10 mg intraventricular (patients < 65 ys)*       x
Cycle 5 was repeated for patients < 65 ys       
Back to article page